How human tumour micro-environment impacts tumour cell biology

Preclinical Oncology Services Limited (PRECOS), a pre-clinical research and development service provider with a specific focus on oncology, will be hosting a new webinar discussing its cutting-edge technology and innovative ideas on in vitro and in vivo modelling of the human tumour micro-environment (TME). The informative web seminar will take place on March 15 2011, 12 - 1pm EDT and will be hosted by Dr Brett Hall, Oncology Biomarker Team Leader, Janssen Pharmaceutica and Professor Sue Watson, Chief Scientific Officer of PRECOS. To register visit: www.cbinet.com/webinars/showWebinar.cfm?confCode=EC11538

The educational webinar will provide an overview of the challenges and opportunities in developing novel therapeutics linked to the human TME and illustrate how the human TME impacts tumour cell biology and drug pharmacology. A number of new oncology targets have arisen through investigations into the TME associated with solid tumours and tumour stem cell characteristics. However due to the level of cancer drug attrition in the clinic, drug discovery programmes are looking to the early pre-clinical phase to optimally challenge new targets, in terms of their potential efficacy, prior to initiating a full drug discovery cascade.

PRECOS appoints Dr Neil Rotherham as chairman

Preclinical Oncology Services Limited (PRECOS), a leading pre-clinical research and development service with a specific focus on oncology, announces the appointment of Dr Neil Rotherham as chairman of the PRECOS board. Dr Rotherham has over 20 years' leadership experience in the life sciences, medical, pharmaceutical and biopharmaceutical sectors.

Dr Rotherham was responsible for developing and growing ClinPhone plc, one of Nottingham's and Europe's most successful clinical technology businesses.